NCT05855863 · Phase 4 · NOT YET RECRUITING
Clinical Study of GKT in Diabetes Related Dementia
This trial is testing Ginkgo Biloba Ketone Ester Tablets against a placebo in older adults who have both Type 2 diabetes and mild cognitive impairment. Researchers want to see whether this herbal extract can improve thinking and memory in a specific dementia subtype linked to diabetes-related brain changes. This is a Phase 4 trial, meaning the drug is already approved for some uses, and this study explores a new application.
You may qualify if
- Type 2 diabetes with mild cognitive impairment patients aged 65 years or above;
- Able to cooperate in completing cognitive function testing;
- Patients who can swallow pills
- No previous history of stroke，cerebral thrombosis, etc
You're excluded if
- Type 1 diabetes;
- Acute cerebral infarction and myocardial infarction within 3 months;
- Severe liver and kidney dysfunction;
- Late stage malignant tumors;
- Thyroid dysfunction；
- Brain injury and cerebral hemorrhage within 3 months；
- Folic acid and/or vitamin B12 deficiency
- Patients who are currently using thrombin inhibitors, defibrillators (with unclear efficacy in ischemic stroke and increased risk of bleeding), antiplatelet drugs, blood activating and stasis resolving agents, and other ginkgo biloba leaf preparations (as they may affect the evaluation of the therapeutic effect of ginkgo biloba ester tablets in this trial), as well as other trial medications.
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2023-11-13